Sonoma Pharmaceuticals, Inc. · NASDAQ:SNOA
Sonoma Pharmaceuticals — Q2 FY2018 Earnings Presentation
11 slides from Sonoma Pharmaceuticals's earnings presentation, Nov 9, 2017
Slide 1: Second Quarter FY2018 Results
SONOMA PHARMACEUTICALS SECOND QUARTER FY2018 RESULTS November 9, 2017 1
Slide 2: Agenda
Page Agenda Welcome / Introduction September 30, 2017 Highlights Q+A Dan McFadden Jim Schutz Marc Umscheid Brand Building and Biz Development Financial Review Bob Miller 2
Slide 3: Forward-Looking Statement
Page Forward - Looking Statement Except for historical information herein, matters set forth in this press release are forward - looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 , including statements about the commercial and technolo
Slide 4: Results from the Quarter Ended September 2017
Page Results from the Quarter Ended 30 September 2017 Total Net Revenue = $ 4,325,000 • Up 55% versus same period last year • Up 13% versus quarter ended 30 Jun 2017 4 US Dermatology Revenue = $ 1,621,000 • Up 53% versus same period last year • Up 36% versus quarter ended 30 June 2017 EBITDA during
Slide 5: 2017 YTD Milestones
Page 2017 YTD Milestones October - Seven Brazilian dermatology approvals September – Launched Loyon, indicated for scaling and erythema for various dermatoses June – Two Singapore dermatology approvals April – Hired 13 additional sales reps, totaling 30 reps and 5 managers April - Two UAE
Slide 6: Differentiated, Effective Solutions for scaling associated with dermatitis
Page 6 Differentiated, Effective Solutions … for scaling associated with dermatitis Loyon® For the Management of Scaling and Itch LOYON® is indicated to manage and relieve the itching, erythema, and scaling experienced with various types of dermatoses, including seborrhea and seborrheic dermatitis.
Slide 7: Loyon patient case: scalp scaling before and after treatment
19 year old male, pronounced scalp scaling Treatment with LOYON 1 x daily for 7 days Before Treatment Day 7 7
Slide 8: Loyon patient case: before treatment and day 7
35 year old female, application of LOYON® 1 X daily without concomitant anti - inflammatory treatment Before Treatment Day 7 8
Slide 9: Sept 2017 QTR vs Sept 2016 QTR & June 2017 QTR
Sept 2017 QTR vs Sept 2016 QTR & June 2017 QTR 9 Quarter Ended Quarter Ended Sept 30, 2016 Quarter Ended June 30, 2017 Sept 30, 2017 Amount Variance Amount Variance Total net revenues $4,325 $2,798 $1,527 $3,835 $490 Product revenues $4,144 $2,574 $1,570 $3,603 $541 U.S. reve
Slide 10: Prescriptions Filled for Dermatology Product Lines
Page 10 Prescriptions Filled for Dermatology Product Lines 0 1,106 2,724 3,361 4,059 3,769 4,809 5,793 6,935 6,287 6,072 7,635 8,686 0 39 1,043 2,305 3,103 2,833 3,339 4,275 4,513 4,103 3,979 5,199 5,612 0 134 476 635 548 786 1,267 1,657 2,487 0 1,084 1,839 1,871 1,671 1,546 1,708 0 100 805 1,143 1,
Slide 11: Total demand dollars quarterly growth by product
Total Q4 $2,552,720 + 7% Total Q4 $2791,258 + 17% Total Q3 $2,393,001 + 15% Total Q4 $2,791,258 + 17% Total Q1 $3.866,209 + 39% Average Quarter over Quarter Growth for Last 4/ 6 Quarters: • Total Demand Dollars Quarterly Growth of 24%/ 37% • Ceramax Quarterly Growth of 13% • Mondoxyne Quarterly Grow
Sonoma Pharmaceuticals — Q2 FY2018 Earnings Presentation on 6ix